Tirzepatide: difference between revisions
Diff·revision 11 → 12·23:56, 29 Oct 2024
Difference between revision 11 and revision 12 of Tirzepatide. 5 lines changed; the page grew by 146 bytes.
| Revision 11 — 05:04, 17 Oct 2024 TelehealthTruus (talk) add the receptor targets to the lead sentence 4,843 bytes +137 | Revision 12 — 23:56, 29 Oct 2024 RetatrutideRuben (talk) copyedit 4,989 bytes +146 | ||
|---|---|---|---|
| 1 | {{Infobox compound | 1 | {{Infobox compound |
| 2 | | name = Tirzepatide | 2 | | name = Tirzepatide |
| + | 3 | | subtitle = Clinical data | |
| 3 | | image = peptide-chain.svg | 4 | | image = peptide-chain.svg |
| 4 | | caption = A 39-residue GIP-based backbone with Aib at positions 2 and 13 and a C-20 diacid on Lys20. | 5 | | caption = A 39-residue GIP-based backbone with Aib at positions 2 and 13 and a C-20 diacid on Lys20. |
| ⋮ | ⋮ | ||
| 12 | | Molar mass = 4,813.45 g·mol⁻¹ | 13 | | Molar mass = 4,813.45 g·mol⁻¹ |
| 13 | | Residues = 39 | 14 | | Residues = 39 |
| + | 15 | <!-- Pharmacokinetics --> | |
| + | 16 | | Half-life = ≈5 days | |
| + | 17 | | Bioavailability, SC = ≈80% | |
| + | 18 | | Time to steady state = 4 weeks | |
| 14 | }} | 19 | }} |
| 15 | {{hatnote|Not to be confused with [[Retatrutide]], which adds glucagon-receptor agonism. For the class, see [[Dual incretin agonist]].}} | 20 | {{hatnote|Not to be confused with [[Retatrutide]], which adds glucagon-receptor agonism. For the class, see [[Dual incretin agonist]].}} |